BriaCell Therapeutics Corp. 8-K

What Happened
On March 31, 2026, BriaCell Therapeutics Corp. disclosed that its subsidiary, BriaPro Therapeutics Corp., filed unaudited condensed interim consolidated financial statements and management’s discussion and analysis (MD&A) for the three- and six-month periods ended January 31, 2026 with the British Columbia and Alberta Securities Commissions. These documents were furnished under Regulation FD and are included as Exhibits 99.1 (financial statements) and 99.2 (MD&A) to the company’s Form 8-K; they are incorporated by reference into the report.

Key Details

• Filed date: March 31, 2026.
• Reporting period: three- and six-month periods ended January 31, 2026.
• Documents filed: unaudited condensed interim consolidated financial statements (Exhibit 99.1) and MD&A (Exhibit 99.2).
• Filings made with: British Columbia Securities Commission and Alberta Securities Commission; Inline XBRL cover page included (Exhibit 104).

Why It Matters
These filings give investors access to BriaPro’s interim financials and management commentary, which can provide insight into the subsidiary’s recent operating and financial performance. The Form 8-K itself does not summarize dollar figures or results — investors should review Exhibits 99.1 and 99.2 for the detailed numbers and management analysis.